Advances in understanding the pathogenetic mechanisms of Alzheimer's disease

Functional Neurology

Volumn 16, Issue 4 SUPPL., 2001, Pages 17-30

  Govoni, Stefano ^a   Lanni, Cristina ^a   Racchi, Marco ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amyloid; Acetylcholinesterase inhibitors; Alzheimer's disease; Amyloid precursor protein; Neurodegeneration; Pathogenesis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; ANTIOXIDANT; BETHANECHOL; BISINDOLYLMALEIMIDE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CYTISINE; DONEPEZIL; EPIBATIDINE; ESTROGEN; GALANTAMINE; GENISTEIN; METRIFONATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUROLEPTIC AGENT; NEUROPEPTIDE; NICOTINE; NICOTINIC RECEPTOR; PHORBOL ESTER; PHYSOSTIGMINE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RIVASTIGMINE; SCAVENGER; STAUROSPORINE; TACRINE; UNINDEXED DRUG; AMYLOID PRECURSOR PROTEIN; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN DEGENERATION; CELL DEATH; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; ENZYME PHOSPHORYLATION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NERVE CELL; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PROTEIN METABOLISM; SECOND MESSENGER; SENILE PLAQUE; SIDE EFFECT; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; METABOLISM; PHYSIOLOGY; REVIEW;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HUMANS; PEPTIDE FRAGMENTS; RECEPTORS, NICOTINIC;

EID: 0035544914     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (93)

1. Uber eine eigenartige Erkrangkung der Himrinde
2. Neuropathological stageing of Alzheimer-related changes
3. Tau protein and the neurofibrillary pathology of Alzheimer's disease
4. Amyloid beta-protein and genetics of Alzheimer's disease
5. Cellular processing of β-amyloid precursor protein and the genesis of amyloid b-peptide
6. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
7. Molecular genetics of Alzheimer's disease
8. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
9. Aβ peptide immunization behavioural impairment and plaques in a model of Alzheimer's disease
10. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
11. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro
12. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs
13. Conformational transition and cellular toxicity by amyloidogenic proteins
14. Impairment of the ubiquitin-proteasome system by protein aggregation
15. Metabolic regulation of brain Aβ by neprilysin
16. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ
17. Mechanisms of neuronal degeneration in Alzheimer's disease
18. β-amyloid polypeptide increases calcium-uptake in PC12 cells: A possible mechanisms for its cellular toxicity in Alzheimer's disease
19. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury and amyloid β-peptide toxicity in hippocampal neurons
20. 2+ homeostasis in Alzheimer's disease
21. Beta amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity
22. Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease
23. Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism
24. Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade
25. Regulation of amyloid precursor protein cataboslim involves the mitogen-activated protein kinase signal transduction pathway
26. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
27. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
28. Association of acetylcholinesterase with the cell surface
29. Special properties of cholinesterase in the cerebral cortex of Alzheimer's disease
30. Colocalization of cholinesterases with β-amyloid protein in aged and Alzheimer's brain
31. Molecular and cellular biology of cholinestearases
32. Acetylcholinesterase, a senile plaque component affects the fibrillogenesis of amyloid-β-peptide
33. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme
34. The carboxy-terminus of the β-amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
35. Cholinergic systems are related neuropathological predilection patterns in Alzheimer disease
36. Stable complexes involving acetylcholinesterase and amyloid-β-peptide change in biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils
37. Neuronal nicotinic acetylcholine receptors
38. Neuronal nicotinic receptors in the human brain
39. 3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease
40. Neuronal nicotinic receptor subtypes
41. 3H]dopamine release
42. Neuronal nicotinic receptor alpha 6 subunit mRNA in selectively concentrated in catecholaminergic nuclei of the rat brain
43. Distribution of nicotinic receptors in the CNS
44. Neuroreceptor changes in Alzheimer disease
45. Nicotinic acetylcholine receptor subtypes in human frontal cortex: Changes in Alzheimer's disease
46. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease - Histotopographical correlation with amyloid plaques and hyperphosphorylated tau protein
47. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
48. Cholinesterase inhibitors do more than inhibit cholinesterase
49. The action of certain esters and ethers of choline, and their relation to muscarine
50. Enhancement of memory by physostigmine
51. Memory enhancement with oral physostigmine in Alzheimer's disease
52. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
53. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex
54. Treatment with metrifonate promotes soluble amyloid precursor protein release from SH-SY5Y neuroblastoma cells
55. Short- and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein
56. Drug therapy: Treatment of Alzheimer's disease
57. Immunochemical demonstration of increased choline acetyltransferase concentration in rat preoptic area after estradiol administration
58. Estradiol protects against β-amyloid(25-35)-induced toxicity in SK-H-SH human neuroblastoma cells
59. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides
60. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship
61. Beta-estradiol attenuates amyloid-β-peptide toxicity via nicotinic receptors and promotes neuroprotection of cholinesterase inhibitors
62. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein
63. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content
64. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons
65. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10
66. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
67. Aging, energy, and oxidative stress in neurodegenerative diseases
68. Emerging neuroprotective strategies for Alzheimer's disease: Dietary restriction, telomerase activation, and stem cell therapy
69. Conditions allowing redox-cycling ubisemiquinone in mitochondria to establish a direct redox couple with molecular oxygen
70. Oxidative stress: From basic research to clinical application
71. Neuronal plasticity and stressor toxicity during aging
72. Oxidative injury in disease of the central nervous system: Focus on Alzheimer's disease
73. Evolution of antioxidant defence mechanisms
74. Plant-derived phenolic antioxidants
75. Antioxidant activity of plant extracts containing phenolic compounds
76. Antioxidant activity of selected Indian spices
77. Antioxidant capacity, vitamin C, phenolics, and anthocyanins after fresh storage of small fruits
78. Phenol antioxidant quantity and quality in foods: Vegetables
79. Antioxidant activity and total phenolics in selected fruits, vegetables, and grain products
80. Antioxidative and protective properties of extracts from leaves of the artichoke (Cynara scolymus L.) against hydroperoxide-induced oxidative stress in cultured rat hepatocytes
81. Inhibition of peroxynitrite dependent DNA base modification and tyrosine nitration by the extra virgin olive oil-derived antioxidant hydroxytyrosol
82. In vitro screening of plant extracts and phytopharmaceuticals: Novel approaches for the elucidation of active compounds and their mechanisms
83. Increased natural killer cell cytotoxicity in Alzheimer's disease may involve protein kinase C dysregulation
84. Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I
85. Neuroinflammation and the genetics of Alzheimer's disease: The search for a pro-inflammatory phenotype
86. The role of complement anaphylatyoxin C5a in neurodegeneration: Implications in Alzheimer's disease
87. Malattia di Alzheimer e processi infiammatori cronici
88. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain
89. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease
90. A randomised controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study
91. Genetic susceptibility factors for Alzheimer's disease